Preclinical and clinical studies on CAR-NK cell therapy: latest update from 2025 ASH Annual Meeting
Abstract Chimeric antigen receptor–engineered natural killer (CAR-NK) cells are emerging as an off-the-shelf immunotherapy for hematologic malignancies, supported by early clinical data and a favorable safety profile. Compared with CAR-T therapy, CAR-NK cells offer the potential for scalable allogen...
Gorde:
| Egile Nagusiak: | , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BMC
2026-05-01
|
| Saila: | Experimental Hematology & Oncology |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1186/s40164-026-00780-6 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|